Among patients with sustained viral suppression in a resource-limited setting, CD4 gains are continuous although gender-based differences occur.

PubWeight™: 0.81‹?›

🔗 View Article (PMC 3754935)

Published in PLoS One on August 27, 2013

Authors

Joseph B Sempa1, Agnes N Kiragga, Barbara Castelnuovo, Moses R Kamya, Yukari C Manabe

Author Affiliations

1: Infectious Diseases Institute, Makerere University, Kampala, Uganda.

Articles cited by this

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med (1998) 53.26

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet (2002) 16.56

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA (2001) 7.63

CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis (2006) 4.67

Failure of immunologic criteria to appropriately identify antiretroviral treatment failure in Uganda. AIDS (2009) 4.54

Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis (2009) 3.91

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

Increased production of IL-7 accompanies HIV-1-mediated T-cell depletion: implications for T-cell homeostasis. Nat Med (2001) 3.69

Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. Lancet (2007) 3.58

CD4 T-lymphocyte recovery in individuals with advanced HIV-1 infection receiving potent antiretroviral therapy for 4 years: the Swiss HIV Cohort Study. Arch Intern Med (2003) 3.41

Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS (2008) 3.31

CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr (2007) 3.18

Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis (2009) 2.82

CD4 cell count recovery among HIV-infected patients with very advanced immunodeficiency commencing antiretroviral treatment in sub-Saharan Africa. BMC Infect Dis (2006) 2.68

Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS (2003) 2.66

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384. J Acquir Immune Defic Syndr (2006) 2.56

Poor CD4 T cell restoration after suppression of HIV-1 replication may reflect lower thymic function. AIDS (2001) 2.47

Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count. J Acquir Immune Defic Syndr (2004) 2.11

Altered clonogenic capability and stromal cell function characterize bone marrow of HIV-infected subjects with low CD4+ T cell counts despite viral suppression during HAART. Clin Infect Dis (2008) 1.74

Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One (2010) 1.72

Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy. J Infect Dis (2004) 1.70

Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection. AIDS (2010) 1.54

Immune reconstitution under antiretroviral therapy: the new challenge in HIV-1 infection. Blood (2011) 1.49

Long-term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs. HIV Med (2007) 1.40

Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. AIDS (1999) 1.33

Increase and plateau of CD4 T-cell counts in the 3(1/2) years after initiation of potent antiretroviral therapy. J Acquir Immune Defic Syndr (2001) 1.29

Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther (2008) 1.22

Long-term patterns in CD4 response are determined by an interaction between baseline CD4 cell count, viral load, and time: The Asia Pacific HIV Observational Database (APHOD). J Acquir Immune Defic Syndr (2009) 1.16

Do sex and race/ethnicity influence CD4 cell response in patients who achieve virologic suppression during antiretroviral therapy? Clin Infect Dis (2003) 1.12

Restoration of the immune system with anti-retroviral therapy. Immunol Lett (1999) 1.12

Gender differences in immune reconstitution: a multicentric cohort analysis in sub-Saharan Africa. PLoS One (2012) 1.10

Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS (1999) 1.04

Long-term trends in CD4 cell counts and impact of viral failure in individuals starting antiretroviral therapy: UK Collaborative HIV Cohort (CHIC) study. HIV Med (2011) 1.03

Low CD4+ T cell nadir is an independent predictor of lower HIV-specific immune responses in chronically HIV-1-infected subjects receiving highly active antiretroviral therapy. J Infect Dis (2006) 1.01

Sex-specific alterations in neutrophil apoptosis: the role of estradiol and progesterone. Blood (2003) 1.00

Evaluation of WHO Criteria for Viral Failure in Patients on Antiretroviral Treatment in Resource-Limited Settings. AIDS Res Treat (2011) 0.94

HIV RNA suppression and immune restoration: can we do better? Clin Dev Immunol (2012) 0.92

Sex-based differences in T lymphocyte responses in HIV-1-seropositive individuals. J Infect Dis (2005) 0.91

Modeling CD4+ cell count increase over a six-year period in HIV-1-infected patients on highly active antiretroviral therapy in Senegal. Am J Trop Med Hyg (2009) 0.90

Evidence that androgens modulate human thymic T cell output. J Investig Med (2011) 0.88

Immune restoration and onset of new AIDS-defining events with combination antiretroviral therapy in HIV type-1-infected immigrants in the Netherlands. Antivir Ther (2010) 0.82

CD4 T-cell responses to combination antiretroviral therapy. Lancet (2007) 0.78

Articles by these authors

Timing of antiretroviral therapy after diagnosis of cryptococcal meningitis. N Engl J Med (2014) 4.91

Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings. Clin Infect Dis (2010) 4.08

Treatment of malaria restricted to laboratory-confirmed cases: a prospective cohort study in Ugandan children. Malar J (2007) 4.05

Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis (2008) 3.91

Predictors of long-term viral failure among ugandan children and adults treated with antiretroviral therapy. J Acquir Immune Defic Syndr (2007) 3.78

Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet (2002) 3.78

Combination therapy for uncomplicated falciparum malaria in Ugandan children: a randomized trial. JAMA (2007) 3.62

Home management of malaria with artemether-lumefantrine compared with standard care in urban Ugandan children: a randomised controlled trial. Lancet (2009) 3.21

Combination treatments for uncomplicated falciparum malaria in Kampala, Uganda: randomised clinical trial. Lancet (2004) 3.12

Response to antiretroviral therapy in HIV-infected patients attending a public, urban clinic in Kampala, Uganda. Clin Infect Dis (2005) 3.00

Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis (2010) 2.86

Effectiveness of quinine versus artemether-lumefantrine for treating uncomplicated falciparum malaria in Ugandan children: randomised trial. BMJ (2009) 2.84

Cause-specific mortality and the contribution of immune reconstitution inflammatory syndrome in the first 3 years after antiretroviral therapy initiation in an urban African cohort. Clin Infect Dis (2009) 2.82

Acceptability of routine HIV counselling and testing, and HIV seroprevalence in Ugandan hospitals. Bull World Health Organ (2008) 2.80

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One (2008) 2.78

Reduced immunopathology and mortality despite tissue persistence in a Mycobacterium tuberculosis mutant lacking alternative sigma factor, SigH. Proc Natl Acad Sci U S A (2002) 2.76

Artemisinin combination therapies for treatment of uncomplicated malaria in Uganda. PLoS Clin Trials (2006) 2.72

Short report: proximity to mosquito breeding sites as a risk factor for clinical malaria episodes in an urban cohort of Ugandan children. Am J Trop Med Hyg (2003) 2.68

Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop (2011) 2.46

Artemether-lumefantrine versus dihydroartemisinin-piperaquine for falciparum malaria: a longitudinal, randomized trial in young Ugandan children. Clin Infect Dis (2009) 2.42

Artemisinin versus nonartemisinin combination therapy for uncomplicated malaria: randomized clinical trials from four sites in Uganda. PLoS Med (2005) 2.33

Comparison of HRP2- and pLDH-based rapid diagnostic tests for malaria with longitudinal follow-up in Kampala, Uganda. Am J Trop Med Hyg (2007) 2.30

Factors determining the heterogeneity of malaria incidence in children in Kampala, Uganda. J Infect Dis (2008) 2.28

Likely health outcomes for untreated acute febrile illness in the tropics in decision and economic models; a Delphi survey. PLoS One (2011) 2.24

Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach. Trop Med Int Health (2015) 2.10

Comparative performance of urinary lipoarabinomannan assays and Xpert MTB/RIF in HIV-infected individuals. AIDS (2014) 2.05

High risk of neutropenia in HIV-infected children following treatment with artesunate plus amodiaquine for uncomplicated malaria in Uganda. Clin Infect Dis (2008) 2.05

Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts. Clin Infect Dis (2012) 1.97

Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg (2003) 1.96

Improved malaria case management through the implementation of a health facility-based sentinel site surveillance system in Uganda. PLoS One (2011) 1.94

Evaluation of portable point-of-care CD4 counter with high sensitivity for detecting patients eligible for antiretroviral therapy. PLoS One (2012) 1.93

Geographic differences in antimalarial drug efficacy in Uganda are explained by differences in endemicity and not by known molecular markers of drug resistance. J Infect Dis (2006) 1.93

Gay and bisexual men in Kampala, Uganda. AIDS Behav (2007) 1.89

Symptomatic hyperlactatemia associated with nucleoside analogue reverse-transcriptase inhibitor use in HIV-infected patients: a report of 24 cases in a resource-limited setting (Uganda). Clin Infect Dis (2007) 1.82

Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82

Integration of HIV and TB services results in improved TB treatment outcomes and earlier prioritized ART initiation in a large urban HIV clinic in Uganda. J Acquir Immune Defic Syndr (2012) 1.79

Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda. PLoS One (2012) 1.77

Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health (2004) 1.74

Estimating the annual entomological inoculation rate for Plasmodium falciparum transmitted by Anopheles gambiae s.l. using three sampling methods in three sites in Uganda. Malar J (2014) 1.73

Evaluating the cost-effectiveness of combination antiretroviral therapy for the prevention of mother-to-child transmission of HIV in Uganda. Bull World Health Organ (2012) 1.72

Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One (2010) 1.72

Burden of tuberculosis in Kampala, Uganda. Bull World Health Organ (2004) 1.69

Linkage to HIV care and survival following inpatient HIV counseling and testing. AIDS Behav (2011) 1.66

Increasing incidence of malaria in children despite insecticide-treated bed nets and prompt anti-malarial therapy in Tororo, Uganda. Malar J (2012) 1.65

Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63

Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ (2011) 1.62

Belief in divine healing can be a barrier to antiretroviral therapy adherence in Uganda. AIDS (2007) 1.62

Diagnostic accuracy of a rapid urine lipoarabinomannan test for tuberculosis in HIV-infected adults. J Acquir Immune Defic Syndr (2014) 1.61

Validation of a simplified method for using molecular markers to predict sulfadoxine-pyrimethamine treatment failure in African children with falciparum malaria. Am J Trop Med Hyg (2003) 1.59

Distinguishing recrudescences from new infections in antimalarial clinical trials: major impact of interpretation of genotyping results on estimates of drug efficacy. Am J Trop Med Hyg (2005) 1.59

Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am J Trop Med Hyg (2004) 1.58

Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children. N Engl J Med (2012) 1.58

Relationship between age, molecular markers, and response to sulphadoxine-pyrimethamine treatment in Kampala, Uganda. Trop Med Int Health (2004) 1.56

Short report: modulation of Mycobacterium tuberculosis infection by Plasmodium in the murine model. Am J Trop Med Hyg (2004) 1.54

Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: a randomized, multisite trial to guide national policy in Uganda. Am J Trop Med Hyg (2005) 1.53

Pharmacokinetics of artemether-lumefantrine and artesunate-amodiaquine in children in Kampala, Uganda. Antimicrob Agents Chemother (2009) 1.52

Missed opportunities for HIV testing and late-stage diagnosis among HIV-infected patients in Uganda. PLoS One (2011) 1.50

Indoor residual spraying of insecticide and malaria morbidity in a high transmission intensity area of Uganda. PLoS One (2012) 1.46

Response to 'Does immune reconstitution promote active tuberculosis in patients receiving highly active antiretroviral therapy?' AIDS, 22 July 2005. AIDS (2005) 1.45

Evaluation of a comprehensive refresher training program in malaria microscopy covering four districts of Uganda. Am J Trop Med Hyg (2011) 1.45

Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized, placebo-controlled trial. Clin Infect Dis (2014) 1.44

Use of the slide positivity rate to estimate changes in malaria incidence in a cohort of Ugandan children. Malar J (2009) 1.43

Incidence of malaria and efficacy of combination antimalarial therapies over 4 years in an urban cohort of Ugandan children. PLoS One (2010) 1.42

Attenuation of late-stage disease in mice infected by the Mycobacterium tuberculosis mutant lacking the SigF alternate sigma factor and identification of SigF-dependent genes by microarray analysis. Infect Immun (2004) 1.41

Deletion of the Mycobacterium tuberculosis resuscitation-promoting factor Rv1009 gene results in delayed reactivation from chronic tuberculosis. Infect Immun (2006) 1.40

Urban malaria: primary caregivers' knowledge, attitudes, practices and predictors of malaria incidence in a cohort of Ugandan children. Trop Med Int Health (2003) 1.40

Antenatal syphilis screening using point-of-care testing in Sub-Saharan African countries: a cost-effectiveness analysis. PLoS Med (2013) 1.39

Fertility and contraceptive decision-making and support for HIV infected individuals: client and provider experiences and perceptions at two HIV clinics in Uganda. BMC Public Health (2013) 1.35

Effect of trimethoprim-sulphamethoxazole on the risk of malaria in HIV-infected Ugandan children living in an area of widespread antifolate resistance. Malar J (2010) 1.34

False-positive results of enzyme immunoassays for human immunodeficiency virus in patients with uncomplicated malaria. J Clin Microbiol (2006) 1.34

Acute HIV-1 infection is highly prevalent in Ugandan adults with suspected malaria. AIDS (2010) 1.32

Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc (2010) 1.30

High T-cell immune activation and immune exhaustion among individuals with suboptimal CD4 recovery after 4 years of antiretroviral therapy in an African cohort. BMC Infect Dis (2011) 1.29

Increasing condom use without reducing HIV risk: results of a controlled community trial in Uganda. J Acquir Immune Defic Syndr (2005) 1.28

Safety and tolerability of combination antimalarial therapies for uncomplicated falciparum malaria in Ugandan children. Malar J (2008) 1.27

Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method. Clin Infect Dis (2012) 1.26

The impact of age, temperature, and parasite density on treatment outcomes from antimalarial clinical trials in Kampala, Uganda. Am J Trop Med Hyg (2004) 1.26

Potential for false positive HIV test results with the serial rapid HIV testing algorithm. BMC Res Notes (2012) 1.24

Early parasite clearance following artemisinin-based combination therapy among Ugandan children with uncomplicated Plasmodium falciparum malaria. Malar J (2014) 1.24

Evaluating tuberculosis case detection via real-time monitoring of tuberculosis diagnostic services. Am J Respir Crit Care Med (2011) 1.24

Provider-initiated HIV testing for paediatric inpatients and their caretakers is feasible and acceptable. Trop Med Int Health (2009) 1.23

Epidemiology and awareness of hypertension in a rural Ugandan community: a cross-sectional study. BMC Public Health (2013) 1.23

Sub-optimal CD4 reconstitution despite viral suppression in an urban cohort on antiretroviral therapy (ART) in sub-Saharan Africa: frequency and clinical significance. AIDS Res Ther (2008) 1.22

Asymptomatic Plasmodium infection and cognition among primary schoolchildren in a high malaria transmission setting in Uganda. Am J Trop Med Hyg (2013) 1.21

Implementation of provider-based electronic medical records and improvement of the quality of data in a large HIV program in Sub-Saharan Africa. PLoS One (2012) 1.20

Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19

An autopsy study describing causes of death and comparing clinico-pathological findings among hospitalized patients in Kampala, Uganda. PLoS One (2012) 1.17

Tuberculosis treatment default among HIV-TB co-infected patients in urban Uganda. Trop Med Int Health (2011) 1.17

Tuberculosis in antiretroviral treatment programs in lower income countries: availability and use of diagnostics and screening. PLoS One (2013) 1.16

HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children. AIDS (2010) 1.16

Mentorship needs at academic institutions in resource-limited settings: a survey at Makerere University College of Health Sciences. BMC Med Educ (2011) 1.15